YJ001 clinical trials
How each study uses YJ001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the YJ001 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 1 |
Who runs them
Industry 3 · Other 0
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. (2) · Yuejia Pharmaceuticals (USA), Inc. (1)
Studies
Open first, then newest update. How each study uses YJ001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- YJ001 Spray for Diabetic Peripheral Neuropathic PainRecruitingPhase 3Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.NCT07859111Written as YJ001 spray simulant
- MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNPRecruitingPhase 1Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.NCT06361108Written as YJ001 for Spray Use
- Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy VolunteersCompletedPhase 1Yuejia Pharmaceuticals (USA), Inc.NCT05451667Written as YJ001 for Spray Use